JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis
- JAMP Pharma Group, leading the volume of prescriptions in Quebec for a third consecutive year1, launches Teriflunomide, a complex generic, offering a more affordable alternative to PrAubagio® (Sanofi).
- JAMP Pharma Group expands its range of specialty products, thus contributing to its ambition to offer healthcare professionals and patients services adapted to their needs.
- JAMP Pharma Group, established in Canada since its beginning, contributes to economic growth here and to a future where all Canadians can live full and healthy lives.
BOUCHERVILLE, QC, May 16th 2022 – JAMP Pharma Group, a Montreal based pharmaceutical company, announces today the launch of PrJAMP Teriflunomide, a generic of the reference product Aubagio® from Sanofi. PrJAMP Teriflunomide is indicated for the treatment of relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability2.
This launch is part of the JAMP Pharma Group’s commitment to offer a diverse range of speciality products for the treatment of multiple sclerosis (“MS”). With Canada having one of the highest rates of MS in the world, it is estimated that more than 90,0003 Canadians living with this disease. The arrival of this generic drug, a quality and more affordable option, will provide better access to patients for this therapy, as well as significant savings for public and private drug insurance plans.
Complementary information about this product
- Available strength and format: carton of 28 tablets of 14 mg containing 1 wallet composed of 2 folded blister cards of 14 tablets per card
JAMP CareTM, an added value program for patients suffering from relapsing-remitting multiple sclerosis and receiving treatment with JAMP Teriflunomide.
Patients receiving treatment of PrJAMP Teriflunomide will be supported by the JAMP CareTM Patient Support Program, a program designed to ensure a seamless transition for healthcare providers and patients by the JAMP Pharma Group.
To know more about JAMP CareTM Patient Support Program, visit www.jampcare-support.ca
About JAMP Pharma Group
JAMP Pharma Group is a Canadian-owned company headquartered in the Montreal area. Having experienced remarkable growth over the past 10 years, JAMP Pharma Group is present in all segments of the pharmaceutical market with a portfolio of close to 300 molecules and is amongst the industry leaders in terms of annual prescription volume1. In addition, with nearly 40 new products authorized for sale by Health Canada in the past year4, JAMP Pharma Group is the Canadian leader in product launches, enhancing the new treatment options available in Canada, including many specialty drugs. The Group also has other divisions, Wampole and Laboratoire Suisse, with more than 180 over-the-counter products including a wide range of vitamins, supplements, and natural products, as well as prescription and branded products from its subsidiary Orimed Pharma.
LinkedIn : JAMP Pharma Group
Information:
Alexandra Lewicki, M.Sc
Director, Marketing and communications
Cellulaire : 514-238-6520
1 Source: Manufacturiers pharmaceutiques ayant le plus haut volume de prescriptions rapportées au Canada de 2017 à 2021. Basé en partie sur les données obtenues sous licence d’IQVIA Solutions Canada Inc., concernant le service d’information suivant : CompuScript, septembre 2017 à août 2021. Tous droits réservés. Cet énoncé n’est pas nécessairement celui d’IQVIA Solutions Canada Inc. ou de l’une de ses sociétés affiliées ou filiales.
2 PrJAMP Teriflunomide Produc Monograph. JAMP Pharma Corporation, May 2022.
3 Multiple Sclerosis Society: https://mssociety.ca/about-ms
4 Source : Pharmaceutical manufacturers with the highest volume of product launches in Canada from 2016 to 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: Canadian Drug Store and Hospital Audit, moving annual total from January to December 2016 to 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.